Person

Matthew Vincent Dolan

Formerly EVP, Strategy & Corporate Dev, Dexcom

Current S&P 500 boards
0
Current roles
0
Open-market buys
$0
Open-market sales
$4.0M

Current roles

From Section 16 filings (Forms 3, 4 and 5) in the last 13 months.

No current S&P 500 role.

Past roles

“Last filing” is the latest Form 3/4/5 for that company, an upper bound on the end date.

  • DXCM
    Dexcom
    EVP, Strategy & Corporate Dev
    Mar 2022 – last filing Jan 2025

Sits alongside

People who currently share a board or management team with this person.

No current colleagues on record.

Open-market trades

Purchases and sales reported on Form 4 at S&P 500 companies.

DateCompanyTypeSharesPriceValue
Jan 29, 2025DXCMSale1,183$86.91$103K
May 15, 2024DXCMSale2,423$126.58$307K
Apr 15, 2024DXCMSale1,990$137.81$274K
Mar 15, 2024DXCMSale1,314$130.77$172K
Mar 15, 2024DXCMSale1,886$129.18$244K
Mar 15, 2024DXCMSale1,003$131.39$132K
Mar 12, 2024DXCMSale6,710$134.41$902K
Sep 1, 2023DXCMSale56$102.32$6K
Mar 16, 2023DXCMSale2,303$115.00$265K
Mar 13, 2023DXCMSale6,229$106.27$662K
Mar 6, 2023DXCMSale226$114.40$26K
Sep 1, 2022DXCMSale5$81.63$408
Mar 17, 2022DXCMSale484$450.00$218K
Mar 16, 2022DXCMSale686$425.00$292K
Mar 15, 2022DXCMSale1,016$412.41$419K

SEC reporting-owner ID (CIK) 1914994 · all filings on EDGAR

Matthew Vincent Dolan | USBoard